PP_1170x120_10-25-21

Regeneron

FDA grants emergency use authorization to Regeneron’s COVID-19 antibody

FDA grants emergency use authorization to Regeneron’s COVID-19 antibody

WASHINGTON — The U.S. Food and Drug Administration on Saturday issued emergency use authorization for Regeneron’s COVID-19 antibody therapy, an experimental treatment given to U.S. President Donald Trump that he said helped cure him of the disease. The FDA said the monoclonal antibodies, casirivimab and imdevimab, should be administered together for the treatment of mild

FDA approves asthma indication for Dupixent (dupilumab)

FDA approves asthma indication for Dupixent (dupilumab)

TARRYTOWN, N.Y. and PARIS — Regeneron Pharmaceuticals, Inc. and Sanofi today announced the U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupixent inhibits the overactive signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13),

Adheris Health